Immune Oncology Biomarkers in Lung Cancer: an Overview

[1] Reck M(2016)Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer N Engl J Med 375 1823-1833

[2] Rodríguez-Abreu D(2016)Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer Ann Oncol 27 1953-1958

[3] Robinson AG(2018)PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project J Thorac Oncol 13 1302-1311

[4] Hui R(2017)PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project J Thorac Oncol 12 208-222

[5] Csőszi T(2019)Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Lancet. 393 1819-1830

[6] Fülöp A(2017)First-line nivolumab in stage IV or recurrent non-small-cell lung Cancer N Engl J Med 376 2415-2426

[7] Gottfried M(2015)Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung Cancer N Engl J Med 373 1627-1639

[8] Peled N(2015)Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 123-135

[9] Tafreshi A(2017)Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Lancet. 389 255-265

[10] Cuffe S(2018)Pembrolizumab plus chemotherapy for squamous non-small-cell lung Cancer N Engl J Med 379 2040-2051

[1] Reck M(2016)Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer N Engl J Med 375 1823-1833

[2] Rodríguez-Abreu D(2016)Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer Ann Oncol 27 1953-1958

[3] Robinson AG(2018)PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project J Thorac Oncol 13 1302-1311

[4] Hui R(2017)PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project J Thorac Oncol 12 208-222

[5] Csőszi T(2019)Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Lancet. 393 1819-1830

[6] Fülöp A(2017)First-line nivolumab in stage IV or recurrent non-small-cell lung Cancer N Engl J Med 376 2415-2426

[7] Gottfried M(2015)Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung Cancer N Engl J Med 373 1627-1639

[8] Peled N(2015)Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 123-135

[9] Tafreshi A(2017)Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Lancet. 389 255-265

[10] Cuffe S(2018)Pembrolizumab plus chemotherapy for squamous non-small-cell lung Cancer N Engl J Med 379 2040-2051